Accuray Incorporated (ARAY) Stock

About Accuray Incorporated

Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.

Accuray Incorporated is led by CEO Stephen R. LaNeve, employs 987 people, headquartered in US, publicly traded since 2007.

Accuray Incorporated (ARAY) stock trades at $0.27 with a market capitalization of $31.64M. The stock is valued at a price-to-earnings (P/E) ratio of -15.50, price-to-book of 0.45, price-to-sales of 0.09. Over the past 52 weeks the stock has ranged between $0.22 and $2.10, and currently trades 87.1% below its 52-week high.

On profitability, Accuray Incorporated generates a return on equity (ROE) of -2.47%, return on capital employed of 9.88%, an operating margin of 1.74%, a net profit margin of -10.76%.

Official website: www.accuray.com